Denali Capital Acquisition Corp. Files 8-K

TL;DR

Denali Capital Acquisition Corp. filed an 8-K detailing its share and warrant structure.

AI Summary

Denali Capital Acquisition Corp. filed an 8-K on July 5, 2024, reporting events as of July 2, 2024. The filing details the company's structure, including ordinary shares and redeemable warrants, and provides its business and mailing address in New York, NY.

Why It Matters

This 8-K filing provides essential corporate information and structure details for Denali Capital Acquisition Corp., which is relevant for investors tracking the company's status and offerings.

Risk Assessment

Risk Level: low — This filing is a routine corporate disclosure and does not contain information that inherently increases risk.

Key Numbers

• 001-41351 — SEC File Number (Identifies the company's filing history with the SEC.)
• 98-1659463 — IRS Employer Identification No. (Company's tax identification number.)

Key Players & Entities

• Denali Capital Acquisition Corp. (company) — Registrant
• July 2, 2024 (date) — Earliest event date
• July 5, 2024 (date) — Filing date
• 437 Madison Avenue, 27th Floor, New York, NY 10022 (address) — Business and Mailing Address

FAQ

Key Financial Figures

• $0.0001 — LC Class A ordinary shares, par value $0.0001 per share DECA The NASDAQ Stock Mar
• $11.50 — ordinary share at an exercise price of $11.50 per share DECAW The NASDAQ Stock Ma

Filing Documents

• ea0208972-8k_denali.htm (8-K) — 33KB
• ea020897201ex99-1_denali.htm (EX-99.1) — 42KB
• ex99-1_001.jpg (GRAPHIC) — 5KB
• ex99-1_002.jpg (GRAPHIC) — 2KB
• 0001213900-24-059541.txt ( ) — 322KB
• deca-20240702.xsd (EX-101.SCH) — 4KB
• deca-20240702_def.xml (EX-101.DEF) — 27KB
• deca-20240702_lab.xml (EX-101.LAB) — 37KB
• deca-20240702_pre.xml (EX-101.PRE) — 25KB
• ea0208972-8k_denali_htm.xml (XML) — 7KB

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. On July 2, 2024, Denali Capital Acquisition Corp. (" Denali "), a Cayman Islands exempted company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, issued a press release to announce that it entered into a letter of intent with Semnur Pharmaceuticals, Inc., a wholly-owned subsidiary of Scilex Holding Company (Nasdaq: SCLX, "Scilex") (" Semnur "), for a potential business combination. There can be no assurance that a definitive merger agreement (the " Merger Agreement ") will be entered into or that the proposed transaction will be consummated. A copy of the press release is attached as Exhibit 99.1 hereto and incorporated by reference herein. The information in this Item 7.01, including Exhibit 99.1 hereto, is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), or otherwise subject to liabilities under that section, and shall not be deemed to be incorporated by reference into the filings of Denali under the Securities Act or the Exchange Act, regardless of any general incorporation language in such filings. This Current Report will not be deemed an admission as to the materiality of any information of the information in this Item 7.01, including Exhibit 99.1.

01. Financial Statement and Exhibits

Item 9.01. Financial Statement and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release, dated July 2, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DENALI CAPITAL ACQUISITION CORP. Date: July 5, 2024 By: /s/ Lei Huang Name: Lei Huang Title: Chief Executive Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR